Jubilant Life Sciences today said it has received approval from the US health regulator to market generic Sporanox capsules, used to treat fungal infections, in the American market.
The company has received approval from the US Food and Drug Administration (USFDA) for Itraconazole capsules, a generic version of Janssen Pharmaceuticals' Sporanox, Jubilant Life Sciences said in a regulatory filing.
As on December 31, 2016 Jubilant had a total of 73 abbreviated new drug applications (ANDAs) for oral solids filled in the US, of which 49 have been approved.
Shares of the company were trading 1.8 per cent up at Rs 720.30 apiece on BSE.
Disclaimer: No Business Standard Journalist was involved in creation of this content
